07/30/15 - 11:03 AM EDT
The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.
07/29/15 - 10:33 AM EDT
MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.
07/28/15 - 04:15 PM EDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
07/28/15 - 10:23 AM EDT
It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.
07/27/15 - 12:42 PM EDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
07/27/15 - 10:30 AM EDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
07/22/15 - 10:41 AM EDT
After 34 years in existence, Xoma still can't develop a drug successfully on its own.
07/22/15 - 07:00 AM EDT
Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.
07/20/15 - 02:10 PM EDT
Biotech investors, circle November 23 and 24 on your calendars. Use a thick black marker. This will be an epic event for biotech investors.
07/20/15 - 07:01 AM EDT
Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.